Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • cagrilintide

    - PMLiVE

    Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease

    While the trials did not meet their primary endpoints, they highlighted important biomarker findings

    - PMLiVE

    Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025

    As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...

    Inizio

    - PMLiVE

    Novo Nordisk reports phase 3 data showing semaglutide reduces liver scarring

    Patients with MASH in the ESSENCE phase 3 trial show semaglutide’s potential to improve liver health

    - PMLiVE

    Pfizer and Metsera agree on merger after bidding war between Pfizer and Novo Nordisk

    The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer

    - PMLiVE

    Novo Nordisk agrees to lower certain drug prices in the US

    The company's semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid

    - PMLiVE

    Novo Nordisk reports sales growth in 2025 as R&D pipeline advances

    Growth driven by increased sales in diabetes and obesity markets

    - PMLiVE

    Novo Nordisk to cuts 9,000 jobs in an effort to streamline its operations

    The transition will help the company meet the rising global demand in the obesity market

    - PMLiVE

    Eli Lilly’s oral weight-loss candidate orforglipron shows promise in late-stage trial

    The company is planning to submit the candidate for regulatory review by the end of the year

    - PMLiVE

    Novo Nordisk’s Alhemo approved by FDA for expanded haemophilia use

    The rare bleeding disorder affects approximately 800,000 people globally

    - PMLiVE

    Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients

    Approximately 38.4 million people in the US are affected by diabetes

    - PMLiVE

    Novo Nordisk appoints Maziar Mike Doustdar as president and CEO

    Doustdar has most recently been serving as Novo’s executive vice president of international operations

    - PMLiVE

    Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa

    The company is planning to submit regulatory applications for the candidate by the end of the year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links